Vaccines are so far proven to be safe, although related adverse events cannot be excluded. The urgency for COVID-19 vaccines determined a dilution of the general expectations of safety and efficacy of vaccination (from safe and effective to safe and effective enough). In many countries, a no-fault program was established to compensate individuals who experienced serious vaccine-related injuries. The impressive number of administrations worldwide and the legal indemnity afforded to manufacturers of approved vaccines that cannot be pursued for compensation fed the debate about the availability of a compensation model for COVID-19 vaccine-related injuries. Several European countries have long introduced a system, Vaccine Injury Compensation Programs, to compensate people who suffer physical harm because of vaccination. In Europe, COVID-19 vaccination is strongly recommended for the general population and in many states is declared mandatory for healthcare workers. In 1992, Italy edited Law no. 210 providing legal protection for individuals who reported injuries after mandatory and recommended vaccinations as a no-fault alternative to the traditional tort system. Despite its recommended nature, COVID-19 vaccination is excluded from the no-fault model in several European states, and the Italian government is called to provide clear and firm instructions for the management of the many requests for compensation. The authors provide an overview of the existing compensation models in Europe and analyse available legislative proposals.

 “First do no harm”. No-fault compensation program for COVID-19 vaccines as feasibility and wisdom of a policy instrument to mitigate vaccine hesitancy / D’Errico, Stefano; Zanon, Martina; Concato, Monica; Peruch, Michela; Scopetti, Matteo; Frati, Paola; Fineschi, Vittorio. - In: VACCINES. - ISSN 2076-393X. - 9:10(2021), pp. 1-14. [10.3390/vaccines9101116]

 “First do no harm”. No-fault compensation program for COVID-19 vaccines as feasibility and wisdom of a policy instrument to mitigate vaccine hesitancy

Matteo Scopetti;Paola Frati;Vittorio Fineschi
2021

Abstract

Vaccines are so far proven to be safe, although related adverse events cannot be excluded. The urgency for COVID-19 vaccines determined a dilution of the general expectations of safety and efficacy of vaccination (from safe and effective to safe and effective enough). In many countries, a no-fault program was established to compensate individuals who experienced serious vaccine-related injuries. The impressive number of administrations worldwide and the legal indemnity afforded to manufacturers of approved vaccines that cannot be pursued for compensation fed the debate about the availability of a compensation model for COVID-19 vaccine-related injuries. Several European countries have long introduced a system, Vaccine Injury Compensation Programs, to compensate people who suffer physical harm because of vaccination. In Europe, COVID-19 vaccination is strongly recommended for the general population and in many states is declared mandatory for healthcare workers. In 1992, Italy edited Law no. 210 providing legal protection for individuals who reported injuries after mandatory and recommended vaccinations as a no-fault alternative to the traditional tort system. Despite its recommended nature, COVID-19 vaccination is excluded from the no-fault model in several European states, and the Italian government is called to provide clear and firm instructions for the management of the many requests for compensation. The authors provide an overview of the existing compensation models in Europe and analyse available legislative proposals.
2021
vaccination; COVID-19; no-fault compensation; adverse events; solidarity; vaccine hesitancy
01 Pubblicazione su rivista::01a Articolo in rivista
 “First do no harm”. No-fault compensation program for COVID-19 vaccines as feasibility and wisdom of a policy instrument to mitigate vaccine hesitancy / D’Errico, Stefano; Zanon, Martina; Concato, Monica; Peruch, Michela; Scopetti, Matteo; Frati, Paola; Fineschi, Vittorio. - In: VACCINES. - ISSN 2076-393X. - 9:10(2021), pp. 1-14. [10.3390/vaccines9101116]
File allegati a questo prodotto
File Dimensione Formato  
D'Errico_First_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 9.1 MB
Formato Adobe PDF
9.1 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1575332
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 13
social impact